Investigating key strategies for optimising clinical trial supply chains in 2025
As the clinical trial landscape evolves with a growing demand for efficiency, flexibility, and innovation in 2025, experts will gather …
Post
-
-
Measles outbreak in the US largest since 2019
The United States is experiencing a multi-state measles outbreak, resulting in the highest case spike since 2019. There are currently …
-
Incyte stock hit 11% despite paediatric dermatology trials hitting target
Incyte’s stock price has taken a hit of more than 11%, despite two Phase III trials investigating its oral small-molecule …
-
Anocca gains European authorisation for Phase I/II trial of pancreatic cancer drug
Swedish immunotherapy company Anocca has secured authorisation from regulatory authorities in four European nations for its Phase I/II VIDAR-1 clinical …
-
Clinical trial challenges in China: How a Sharp and ClinsChain pairing is breaking down barriers
The market for clinical trials in China is currently experiencing significant growth, driven by increasing activity from both Chinese sponsors …
-
Dyne’s DMD trial advances patient mobility and dystrophin expression
Patients with Duchenne muscular dystrophy (DMD) have seen an “unprecedented and sustained” functional improvement in a Phase I/II trial examining …
-
Scholar Rock SMA drug shows muscle function benefit
Scholar Rock’s spinal muscular atrophy (SMA) therapy has shown benefit in muscle function in children under 12 in a pivotal …
-
World Tuberculosis Day 2025: the end of TB is possible
The international community will celebrate World Tuberculosis Day on Monday, 24 March this year. The theme for 2025 is “Yes! …
-
Palisade Bio begins dosing subjects in last cohort of ulcerative colitis drug trial
US-based biopharmaceutical company Palisade Bio has begun dosing subjects in the last cohort of its Phase Ia/b trial of PALI-2108 …
-
AbbVie reports final analysis from Phase III trial of Elahere for ovarian cancer
US-based pharmaceutical company AbbVie has reported the final analysis from the Phase III MIRASOL trial, which assessed its antibody-drug conjugate …
-
INOVIO’s Covid-19 dMAb maintains in-vivo detection in 100% participants
INOVIO’s DNA-encoded monoclonal antibodies (dMAbs) have been able to maintain biologically relevant levels in 100% of Covid-19 in a Phase …
-
BioCity and MSD to evaluate cancer treatment combination in Phase I/II trial
BioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with the latter’s Keytruda (pembrolizumab) …
-
NHS approves long-term daily pill for endometriosis in England
The National Health Service (NHS) in England has approved Gedeon Richter’s Ryeqo (relugolix + estradiol + norethisterone), the first long-term …
-
Blue Earth’s radioligand therapy achieves high tumour radiation absorption
Blue Earth Therapeutics’s injectable investigational radioligand therapy, Lutetium rhPSMA-10.1, has led to higher doses of radiation in tumours than healthy …
-
SRC approves opening of TransCode’s fourth cohort in trial of TTX-MC138
A US Safety Review Committee (SRC) has granted unanimous approval for TransCode Therapeutics to open the fourth cohort in its …
